{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:36:03Z","timestamp":1777008963486,"version":"3.51.4"},"reference-count":40,"publisher":"e-Century Publishing Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/odwl5634","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T03:33:48Z","timestamp":1738899228000},"page":"271-285","source":"Crossref","is-referenced-by-count":3,"title":["Tumor Treating Fields enhance chemotherapy efficacy by increasing cellular drug uptake and retention in mesothelioma cells"],"prefix":"10.62347","volume":"15","author":[{"given":"Rosy","family":"Amodeo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/oem.51.12.804","article-title":"Malignant mesothelioma: attributable risk of asbestos exposure","volume":"51","author":"Spirtas","year":"1994","unstructured":"Spirtas R, Heineman EF, Bernstein L, Beebe GW, Keehn RJ, Stark A, Harlow BL and Benichou J. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med 1994; 51: 804-811.","journal-title":"Occup Environ Med"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/jso.27152","article-title":"Contemporary issues in the surgical management of pleural mesothelioma","volume":"127","author":"Paajanen","year":"2023","unstructured":"Paajanen J, Jaklitsch MT and Bueno R. Contemporary issues in the surgical management of pleural mesothelioma. J Surg Oncol 2023; 127: 343-354.","journal-title":"J Surg Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C and Zalcman G. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021; 397: 375-386.","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"104372","DOI":"10.1016\/j.critrevonc.2024.104372","article-title":"Evaluation of first-line and salvage therapies for unresectable malignant mesothelioma: a systematic review and network meta-analysis","volume":"198","author":"Zhuang","year":"2024","unstructured":"Zhuang W, Liu L, Sun B, Bai H, Wang Z, Duan J, Wan R, Ma Z, Zhong J and Wang J. Evaluation of first-line and salvage therapies for unresectable malignant mesothelioma: a systematic review and network meta-analysis. Crit Rev Oncol Hematol 2024; 198: 104372.","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/14656566.2022.2072211","article-title":"Advances in drug treatments for mesothelioma","volume":"23","author":"PA","year":"2022","unstructured":"Zucali PA, De Vincenzo F, Perrino M, Digiacomo N, Cordua N, D’Antonio F, Borea F, Fazio R, Pirozzi A and Santoro A. Advances in drug treatments for mesothelioma. Expert Opin Pharmacother 2022; 23: 929-946.","journal-title":"Expert Opin Pharmacother"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/S1470-2045(19)30532-7","article-title":"Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial","volume":"20","author":"GL","year":"2019","unstructured":"Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crinò L, Krzakowski M, Rüssel J, Maconi A, Gianoncelli L and Grosso F. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol 2019; 20: 1702-1709.","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.3390\/cells11172712","article-title":"Real-time monitoring of the effect of Tumour-Treating Fields on cell division using live-cell imaging","volume":"11","author":"HT","year":"2022","unstructured":"Le HT, Staelens M, Lazzari D, Chan G and Tuszyński JA. Real-time monitoring of the effect of Tumour-Treating Fields on cell division using live-cell imaging. Cells 2022; 11: 2712.","journal-title":"Cells"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"18046","DOI":"10.1038\/srep18046","article-title":"Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells","volume":"5","author":"Giladi","year":"2015","unstructured":"Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, Cahal S, Shteingauz A, Chaudhry A, Kirson ED, Weinberg U and Palti Y. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep 2015; 5: 18046.","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1158\/0008-5472.CAN-22-0887","article-title":"The mechanisms of action of Tumor Treating Fields","volume":"82","author":"Moser","year":"2022","unstructured":"Moser JC, Salvador E, Deniz K, Swanson K, Tuszynski J, Carlson KW, Karanam NK, Patel CB, Story M, Lou E and Hagemann C. The mechanisms of action of Tumor Treating Fields. Cancer Res 2022; 82: 3650-3658.","journal-title":"Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41420-022-01206-y","article-title":"The schemes, mechanisms and molecular pathway changes of Tumor Treating Fields (TTFields) alone or in combination with radiotherapy and chemotherapy","volume":"8","author":"Tanzhu","year":"2022","unstructured":"Tanzhu G, Chen L, Xiao G, Shi W, Peng H, Chen D and Zhou R. The schemes, mechanisms and molecular pathway changes of Tumor Treating Fields (TTFields) alone or in combination with radiotherapy and chemotherapy. Cell Death Discov 2022; 8: 416.","journal-title":"Cell Death Discov"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.3390\/cancers15235642","article-title":"Research progress on the mechanism of anti-tumor immune response induced by TTFields","volume":"15","author":"Lan","year":"2023","unstructured":"Lan Y, Zhang S, Pan Y, Wang M and Chen G. Research progress on the mechanism of anti-tumor immune response induced by TTFields. Cancers (Basel) 2023; 15: 5642.","journal-title":"Cancers (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41420-018-0130-x","article-title":"Tumor treating fields increases membrane permeability in glioblastoma cells","volume":"4","author":"Chang","year":"2018","unstructured":"Chang E, Patel CB, Pohling C, Young C, Song J, Flores TA, Zeng Y, Joubert LM, Arami H, Natarajan A, Sinclair R and Gambhir SS. Tumor treating fields increases membrane permeability in glioblastoma cells. Cell Death Discov 2018; 4: 113.","journal-title":"Cell Death Discov"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME and Ram Z. Effect of Tumor-Treating Fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 2017; 318: 2306-2316.","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.3390\/cancers14061568","article-title":"Tumor Treating Fields concomitant with sorafenib in advanced hepatocellular cancer: results of the HEPANOVA phase II study","volume":"14","author":"Gkika","year":"2022","unstructured":"Gkika E, Grosu AL, Macarulla Mercade T, Cubillo Gracián A, Brunner TB, Schultheiß M, Pazgan-Simon M, Seufferlein T and Touchefeu Y. Tumor Treating Fields concomitant with sorafenib in advanced hepatocellular cancer: results of the HEPANOVA phase II study. Cancers (Basel) 2022; 14: 1568.","journal-title":"Cancers (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3390\/cancers15030636","article-title":"Tumor Treating Fields (TTFields) therapy concomitant with taxanes for cancer treatment","volume":"15","author":"Vergote","year":"2023","unstructured":"Vergote I, Macarulla T, Hirsch FR, Hagemann C and Miller DS. Tumor Treating Fields (TTFields) therapy concomitant with taxanes for cancer treatment. Cancers (Basel) 2023; 15: 636.","journal-title":"Cancers (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S1470-2045(23)00344-3","article-title":"Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study","volume":"24","author":"Leal","year":"2023","unstructured":"Leal T, Kotecha R, Ramlau R, Zhang L, Milanowski J, Cobo M, Roubec J, Petruzelka L, Havel L, Kalmadi S, Ward J, Andric Z, Berghmans T, Gerber DE, Kloecker G, Panikkar R, Aerts J, Delmonte A, Pless M, Greil R, Rolfo C, Akerley W, Eaton M, Iqbal M and Langer C; LUNAR Study Investigators. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Lancet Oncol 2023; 24: 1002-1017.","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.lungcan.2021.08.011","article-title":"Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models","volume":"160","author":"Mumblat","year":"2021","unstructured":"Mumblat H, Martinez-Conde A, Braten O, Munster M, Dor-On E, Schneiderman RS, Porat Y, Voloshin T, Davidi S, Blatt R, Shteingauz A, Tempel-Brami C, Zeevi E, Lajterer C, Shmueli Y, Danilov S, Haber A, Giladi M, Weinberg U, Kinzel A and Palti Y. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models. Lung Cancer 2021; 160: 99-110.","journal-title":"Lung Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1002\/ijc.30406","article-title":"Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo","volume":"139","author":"Voloshin","year":"2016","unstructured":"Voloshin T, Munster M, Blatt R, Shteingauz A, Roberts PC, Schmelz EM, Giladi M, Schneiderman RS, Zeevi E, Porat Y, Bomzon Z, Urman N, Itzhaki A, Cahal S, Kirson ED, Weinberg U and Palti Y. Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo. Int J Cancer 2016; 139: 2850-2858.","journal-title":"Int J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11060-023-04308-4","article-title":"Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines","volume":"163","author":"Fishman","year":"2023","unstructured":"Fishman H, Monin R, Dor-On E, Kinzel A, Haber A, Giladi M, Weinberg U and Palti Y. Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines. J Neurooncol 2023; 163: 83-94.","journal-title":"J Neurooncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41419-022-05073-4","article-title":"Tumor Treating Fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations","volume":"13","author":"Mannarino","year":"2022","unstructured":"Mannarino L, Mirimao F, Panini N, Paracchini L, Marchini S, Beltrame L, Amodeo R, Grosso F, Libener R, De Simone I, Ceresoli GL, Zucali PA, Lupi M and D’Incalci M. Tumor Treating Fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations. Cell Death Dis 2022; 13: 612.","journal-title":"Cell Death Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/ijc.30412","article-title":"Promising in vivo efficacy of the BET bromodomain inhibitor OTX015\/MK-8628 in malignant pleural mesothelioma xenografts","volume":"140","author":"V&#xE1","year":"2017","unstructured":"Vázquez R, Licandro SA, Astorgues-Xerri L, Lettera E, Panini N, Romano M, Erba E, Ubezio P, Bello E, Libener R, Orecchia S, Grosso F, Riveiro ME, Cvitkovic E, Bekradda M, D’Incalci M and Frapolli R. Promising in vivo efficacy of the BET bromodomain inhibitor OTX015\/MK-8628 in malignant pleural mesothelioma xenografts. Int J Cancer 2017; 140: 197-207.","journal-title":"Int J Cancer"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Porat Y, Giladi M, Schneiderman RS, Blat R, Shteingauz A, Zeevi E, Munster M, Voloshin T, Kaynan N, Tal O, Kirson ED, Weinberg U and Palti Y. Determining the optimal inhibitory frequency for cancerous cells using Tumor Treating Fields (TTFields). J Vis Exp 2017; 55820.","DOI":"10.3791\/55820"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/19466315.2018.1437071","article-title":"Evaluation of drug combination effect using a Bliss independence dose-response surface model","volume":"10","author":"Liu","year":"2018","unstructured":"Liu Q, Yin X, Languino LR and Altieri DC. Evaluation of drug combination effect using a Bliss independence dose-response surface model. Stat Biopharm Res 2018; 10: 112-122.","journal-title":"Stat Biopharm Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1402851","DOI":"10.3389\/fonc.2024.1402851","article-title":"Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance","volume":"14","author":"Berckmans","year":"2024","unstructured":"Berckmans Y, Ene HM, Ben-Meir K, Martinez-Conde A, Wouters R, Van den Ende B, Van Mechelen S, Monin R, Frechtel-Gerzi R, Gabay H, Dor-On E, Haber A, Weinberg U, Vergote I, Giladi M, Coosemans A and Palti Y. Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance. Front Oncol 2024; 14: 1402851.","journal-title":"Front Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/life12060897","article-title":"Multidrug resistance of cancer cells and the vital role of P-glycoprotein","volume":"12","author":"Karthika","year":"2022","unstructured":"Karthika C, Sureshkumar R, Zehravi M, Akter R, Ali F, Ramproshad S, Mondal B, Tagde P, Ahmed Z, Khan FS, Rahman MH and Cavalu S. Multidrug resistance of cancer cells and the vital role of P-glycoprotein. Life (Basel) 2022; 12: 897.","journal-title":"Life (Basel)"},{"key":"ref25","unstructured":"Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000; 65: 95-106."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s12094-020-02532-2","article-title":"SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)","volume":"23","author":"Nadal","year":"2021","unstructured":"Nadal E, Bosch-Barrera J, Cedrés S, Coves J, García-Campelo R, Guirado M, López-Castro R, Ortega AL, Vicente D and de Castro-Carpeño J. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020). Clin Transl Oncol 2021; 23: 980-987.","journal-title":"Clin Transl Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0304-3835(97)00539-9","article-title":"Actin organization associated with the expression of multidrug resistant phenotype in osteosarcoma cells and the effect of actin depolymerization on drug resistance","volume":"126","author":"Takeshita","year":"1998","unstructured":"Takeshita H, Kusuzaki K, Ashihara T, Gebhardt MC, Mankin HJ and Hirasawa Y. Actin organization associated with the expression of multidrug resistant phenotype in osteosarcoma cells and the effect of actin depolymerization on drug resistance. Cancer Lett 1998; 126: 75-81.","journal-title":"Cancer Lett"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"7638","DOI":"10.1038\/s41598-019-43947-4","article-title":"Methyl-β-cyclodextrin, an actin depolymerizer augments the antiproliferative potential of microtubule-targeting agents","volume":"9","author":"Mundhara","year":"2019","unstructured":"Mundhara N, Majumder A and Panda D. Methyl-β-cyclodextrin, an actin depolymerizer augments the antiproliferative potential of microtubule-targeting agents. Sci Rep 2019; 9: 7638.","journal-title":"Sci Rep"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"183468","DOI":"10.1016\/j.bbamem.2020.183468","article-title":"Actin networks regulate the cell membrane permeability during electroporation","volume":"1863","author":"Muralidharan","year":"2021","unstructured":"Muralidharan A, Rems L, Kreutzer MT and Boukany PE. Actin networks regulate the cell membrane permeability during electroporation. Biochim Biophys Acta Biomembr 2021; 1863: 183468.","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.3390\/cancers12103016","article-title":"Tumor Treating Fields (TTFields) hinder cancer cell motility through regulation of microtubule and acting dynamics","volume":"12","author":"Voloshin","year":"2020","unstructured":"Voloshin T, Schneiderman RS, Volodin A, Shamir RR, Kaynan N, Zeevi E, Koren L, Klein-Goldberg A, Paz R, Giladi M, Bomzon Z, Weinberg U and Palti Y. Tumor Treating Fields (TTFields) hinder cancer cell motility through regulation of microtubule and acting dynamics. Cancers (Basel) 2020; 12: 3016.","journal-title":"Cancers (Basel)"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1126\/science.6681676","article-title":"Latrunculins: novel marine toxins that disrupt microfilament organization in cultured cells","volume":"219","author":"Spector","year":"1983","unstructured":"Spector I, Shochet NR, Kashman Y and Groweiss A. Latrunculins: novel marine toxins that disrupt microfilament organization in cultured cells. Science 1983; 219: 493-495.","journal-title":"Science"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","article-title":"Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance","volume":"15","author":"Gonen","year":"2012","unstructured":"Gonen N and Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 2012; 15: 183-210.","journal-title":"Drug Resist Updat"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3389\/fonc.2020.00265","article-title":"Perplexing role of P-glycoprotein in tumor microenvironment","volume":"10","author":"Robinson","year":"2020","unstructured":"Robinson K and Tiriveedhi V. Perplexing role of P-glycoprotein in tumor microenvironment. Front Oncol 2020; 10: 265.","journal-title":"Front Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/1471-2407-10-229","article-title":"TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters","volume":"10","author":"Schneiderman","year":"2010","unstructured":"Schneiderman RS, Shmueli E, Kirson ED and Palti Y. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters. BMC Cancer 2010; 10: 229.","journal-title":"BMC Cancer"},{"key":"ref35","unstructured":"Kim JS, Cho JM, Kim H, Jeong YK, Kim JK and Kim EH. Tumor treating fields can effectively overcome trastuzumab resistant breast cancer multiplication. Am J Cancer Res 2021; 11: 3935-3945."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1158\/1538-7445.AM2024-4762","article-title":"Abstract 4762: Tumor Treating Fields (TTFields) increase cancer cell membrane permeability and improve sensitivity to doxorubicin in vitro and in vivo","volume":"84","author":"Koltun","year":"2024","unstructured":"Koltun B, Voloshin T, Kan T, David C, Koren L, Porat Y, Volodin A, Kaynan N, Klein-Goldberg A, Paz R, Brant B, Barsheshet Y, Zemer-Tov E, Haber A, Giladi M, Weinberg U and Palti Y. Abstract 4762: Tumor Treating Fields (TTFields) increase cancer cell membrane permeability and improve sensitivity to doxorubicin in vitro and in vivo. Cancer Res 2024; 84: 4762.","journal-title":"Cancer Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.3390\/biom12101348","article-title":"Tumor Treating Fields (TTFields) reversibly permeabilize the blood-brain barrier in vitro and in vivo","volume":"12","author":"Salvador","year":"2022","unstructured":"Salvador E, Kessler AF, Domröse D, Hörmann J, Schaeffer C, Giniunaite A, Burek M, Tempel-Brami C, Voloshin T, Volodin A, Zeidan A, Giladi M, Ernestus RI, Löhr M, Förster CY and Hagemann C. Tumor Treating Fields (TTFields) reversibly permeabilize the blood-brain barrier in vitro and in vivo. Biomolecules 2022; 12: 1348.","journal-title":"Biomolecules"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Mossel P, Bartels AL, de Deyn PP and Luurtsema G. The role of P-glycoprotein at the blood-brain barrier in neurological and psychiatric disease. PET and SPECT in Psychiatry. In: Dierck RA, de Vries E, Otte A, van Waarde A, Sommer IE, editors. Cham: Springer; 2020. pp. 45-81.","DOI":"10.1007\/978-3-030-57231-0_3"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1345190","DOI":"10.3389\/fonc.2024.1345190","article-title":"Tumor Treating Fields in glioblastoma: long-term treatment and high compliance as favorable prognostic factors","volume":"14","author":"Wang","year":"2024","unstructured":"Wang J, Du Q, Chen J, Liu J, Gu Z, Wang X, Zhang A, Gao S, Shao A, Zhang J and Wang Y. Tumor Treating Fields in glioblastoma: long-term treatment and high compliance as favorable prognostic factors. Front Oncol 2024; 14: 1345190.","journal-title":"Front Oncol"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/1\/ajcr0158988.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:50:42Z","timestamp":1766022642000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/1\/ajcr0158988.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/odwl5634","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}